http://www.endo.com/investors/overview
ENDO - Revenue Mix
Endo Pharma 56%
Qualist 20%
Healthtronics 7%
American Medical Systems 17%
Pain – Leader in Pain Management
~$1.8B in sales across business in pain management in 2012
9 out of 10 pain medications currently filled by generic products
7 out of 10 pain medications can be filled by our portfolio
U.S. Chronic Pain Market was valued to be $14B in 2010
Pipeline of products to solidify leadership position
Urology – Market Leader in Devices with Leading Distribution Channel
Aging demographics support growth
US urological market to reach $6.3 billion by 2017; 4% CAGR
Minimally invasive procedures expand markets
Unique market position and channel enhance product uptake
International opportunities for growth
Slide 16 is interesting regarding AMS and HTRN.
"Organic growth"........double digits.
1/3 of US Urologists in EMR relationship with Healthtronics by the end of 2013.
Keep 30% Lidoderm sales even with a generic out there.
Accerlerate mid-single digit AMS sales growth throughout 2015
Qualitest sustained double digit growth with a 15% annual capacity expansion throughour 2015
Return to strong Rx growth with Opana ER and Voltaren Gel in 2013
Qualitest Key Takeaways
o Double-digit net sales growth expected through 2015
o Sustained gross margins expected through 2015
o Capacity expansion and pricing flexibility drive topline growth
o 15% annual increases in capacity planned through 2015
o Pricing flexibility driven by portfolio optimization
o Leader and expert in controlled substances and liquids supports future growth
o Sizable ANDA portfolio in higher value lines of business
AMS
WH 31%
MH 47%
BPH 22%
ED $584M US opportunity / $1.7B globally
MC $200M global opportunity / 60% penetration
FC 31% Market Share
OPPORTUNITY
•$1.2B US
•$2.1B Globally
•21% US
•17% Globally
PFR 40% Market Share
OPPORTUNITY
•$465M US
•$1.0B Globally
•28% US
•24% Globally
BPH Opportunity is $221M in the U.S. - $887M Globally
19.3% penetration of BPH procedures in US – 7.1% globally
AMS Key Takeaways
Strong organic growth opportunities remain within AMS core business lines – mid-to-high single digit CAGR 2012-2015
AMS is uniquely positioned in urologyoLeverage Endo partnership to enhance leadership in urology
Expect to return operating margin to historical levels (high 20 percent to low 30 percent by 2014)
Opportunities in adjacent spaces with existing customers
HealthTronics Key Takeaways
HealthTronics has deep, durable relationships with the US-based Urology community
HealthTronics has a stable, core business that is profitable and cash flow positive
HealthTronics has several platforms for growth including Cryotherapy, Electronic Medical Records and Data-Enabled Services & Analytics
oHealthTronics, through its channel presence in Urology, has strategic value for the Endo enterprise
Lithotripsy: Shock wave destruction of kidney stones
BPH Laser & Cryoablation: Prostate health therapies
Urochart and Meridian: Electronic medical record systems specifically geared for urologists
Anatomic pathology
AGAIN - SLIDE 50 SHOWS BPH AND CRYO TOGETHER
HealthTronics is leading mobile provider of Cryotherapy equipment with 65% market share
HealthTronics’ trusted relationships with urologists has enabled trial of GreenLight XPS®
We expect peak sales in excess of $800 million for Opana® ER
Opportunity
Maximize contribution after Loss of Exclusivity Action
Shift from a sales force promotion to a service model
Integrate non-personal promotion
Implement novel commercial strategies following loss of exclusivity
WHAT DO THEY MEAN "SERVICE MODEL" AND "NON-PERSONAL PROMOTION"?
Voltaten Gel
From 2009 to 2012:
44% reduction in Advertising & Promotion Expense
7% reduction in Physician Detail Equivalents
Urology
Optimize business performance of Urology Portfolio Action
VALSTAR®: Clinical differentiation drove net sales CAGR of over 100% since 2009
SUPPRELIN® LA: Market leading position resulting from net sales CAGR of 29.5% since 2009
FORTESTA® Gel: High growth Testosterone Replacement Therapy category entrant
WOW - SUPPRELIN LA IS THE MARKET LEADER..........THERE ISN'T A COMPETITOR.
BEMA® Buprenorphine: Q4 2015 Launch Expected
Management of moderate to severe chronic pain
Lower abuse potential
Peak year sales over $400M
Strong Intellectual Property estate provides exclusivity until 2027
Urocidin
•Regulatory meetings in October 2012
•Submission Q3 2014
•Launch 2H 2015
TOPAS® Female Fecal Incontinence Mesh System
Clinical study completion 1H 2013
•Submission 2H 2013
•Launch 2H 2014
Merit A New Approach To Treat Female Mild-To-Moderate Stress Urinary Incontinence
$70MM Estimated Base Case Peak Year Sales
2012 Guidance - Revenues $3.05B to $3.175B
Slide 91 - AMS and Healthtronics are together.
ENDO - Revenue Mix
Endo Pharma 56%
Qualist 20%
Healthtronics 7%
American Medical Systems 17%
Pain – Leader in Pain Management
~$1.8B in sales across business in pain management in 2012
9 out of 10 pain medications currently filled by generic products
7 out of 10 pain medications can be filled by our portfolio
U.S. Chronic Pain Market was valued to be $14B in 2010
Pipeline of products to solidify leadership position
Urology – Market Leader in Devices with Leading Distribution Channel
Aging demographics support growth
US urological market to reach $6.3 billion by 2017; 4% CAGR
Minimally invasive procedures expand markets
Unique market position and channel enhance product uptake
International opportunities for growth
Slide 16 is interesting regarding AMS and HTRN.
"Organic growth"........double digits.
1/3 of US Urologists in EMR relationship with Healthtronics by the end of 2013.
Keep 30% Lidoderm sales even with a generic out there.
Accerlerate mid-single digit AMS sales growth throughout 2015
Qualitest sustained double digit growth with a 15% annual capacity expansion throughour 2015
Return to strong Rx growth with Opana ER and Voltaren Gel in 2013
Qualitest Key Takeaways
o Double-digit net sales growth expected through 2015
o Sustained gross margins expected through 2015
o Capacity expansion and pricing flexibility drive topline growth
o 15% annual increases in capacity planned through 2015
o Pricing flexibility driven by portfolio optimization
o Leader and expert in controlled substances and liquids supports future growth
o Sizable ANDA portfolio in higher value lines of business
AMS
WH 31%
MH 47%
BPH 22%
ED $584M US opportunity / $1.7B globally
MC $200M global opportunity / 60% penetration
FC 31% Market Share
OPPORTUNITY
•$1.2B US
•$2.1B Globally
•21% US
•17% Globally
PFR 40% Market Share
OPPORTUNITY
•$465M US
•$1.0B Globally
•28% US
•24% Globally
BPH Opportunity is $221M in the U.S. - $887M Globally
19.3% penetration of BPH procedures in US – 7.1% globally
AMS Key Takeaways
Strong organic growth opportunities remain within AMS core business lines – mid-to-high single digit CAGR 2012-2015
AMS is uniquely positioned in urologyoLeverage Endo partnership to enhance leadership in urology
Expect to return operating margin to historical levels (high 20 percent to low 30 percent by 2014)
Opportunities in adjacent spaces with existing customers
HealthTronics Key Takeaways
HealthTronics has deep, durable relationships with the US-based Urology community
HealthTronics has a stable, core business that is profitable and cash flow positive
HealthTronics has several platforms for growth including Cryotherapy, Electronic Medical Records and Data-Enabled Services & Analytics
oHealthTronics, through its channel presence in Urology, has strategic value for the Endo enterprise
Lithotripsy: Shock wave destruction of kidney stones
BPH Laser & Cryoablation: Prostate health therapies
Urochart and Meridian: Electronic medical record systems specifically geared for urologists
Anatomic pathology
AGAIN - SLIDE 50 SHOWS BPH AND CRYO TOGETHER
HealthTronics is leading mobile provider of Cryotherapy equipment with 65% market share
HealthTronics’ trusted relationships with urologists has enabled trial of GreenLight XPS®
We expect peak sales in excess of $800 million for Opana® ER
Opportunity
Maximize contribution after Loss of Exclusivity Action
Shift from a sales force promotion to a service model
Integrate non-personal promotion
Implement novel commercial strategies following loss of exclusivity
WHAT DO THEY MEAN "SERVICE MODEL" AND "NON-PERSONAL PROMOTION"?
Voltaten Gel
From 2009 to 2012:
44% reduction in Advertising & Promotion Expense
7% reduction in Physician Detail Equivalents
Urology
Optimize business performance of Urology Portfolio Action
VALSTAR®: Clinical differentiation drove net sales CAGR of over 100% since 2009
SUPPRELIN® LA: Market leading position resulting from net sales CAGR of 29.5% since 2009
FORTESTA® Gel: High growth Testosterone Replacement Therapy category entrant
WOW - SUPPRELIN LA IS THE MARKET LEADER..........THERE ISN'T A COMPETITOR.
BEMA® Buprenorphine: Q4 2015 Launch Expected
Management of moderate to severe chronic pain
Lower abuse potential
Peak year sales over $400M
Strong Intellectual Property estate provides exclusivity until 2027
Urocidin
•Regulatory meetings in October 2012
•Submission Q3 2014
•Launch 2H 2015
TOPAS® Female Fecal Incontinence Mesh System
Clinical study completion 1H 2013
•Submission 2H 2013
•Launch 2H 2014
Merit A New Approach To Treat Female Mild-To-Moderate Stress Urinary Incontinence
$70MM Estimated Base Case Peak Year Sales
2012 Guidance - Revenues $3.05B to $3.175B
Slide 91 - AMS and Healthtronics are together.